ConductScience.org, home

Paper25220191

Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis.

Eng C and 3 others. Lancet, 2014. Cited by 299 papers, by iCite.

Cite this record

ConductScience Library. Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis. Papers, record 25220191. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/25220191

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis.
PubMed
Journal
Lancet
PubMed
Year
2014
PubMed
Publication types
Journal Article, Meta-Analysis, Systematic Review
PubMed
Citations, by iCite
299
iCite
Relative citation ratio, by iCite
10.6
iCite
Revised in PubMed
2026-01-28
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Eng CConrad
2Kramer CKCaroline K
3Zinman BBernard
4Retnakaran RRavi

Source PubMed

Download CSV of authors

Topics9

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Diabetes Mellitus, Type 2Major topic
Hypoglycemic AgentsMajor topic
Insulin, Long-ActingMajor topic
Receptors, GlucagonMajor topic
Drug Therapy, Combination
Glycated Hemoglobin
Humans
Randomized Controlled Trials as Topic
Weight Loss

Source PubMed

Download CSV of topics

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT06894784A Clinical Trial to Evaluate The Effects of Semaglutide and Empagliflozin Combined to Automated Insulin Delivery on Diabetes Control in Adults Living With Type 1 DiabetesBackground

Source ClinicalTrials.gov

Download CSV of trials

Comments and corrections2

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn PapersSource
Comment in25220193GLP-1 receptor agonists and basal insulin in type 2 diabetes.https://conductscience.org/library/papers/25220193PubMed
Comment in25599366Review: in type 2 diabetes, GLP-1 agonists plus basal insulin reduce HbA1c without increasing hypoglycemia.https://conductscience.org/library/papers/25599366PubMed

Download CSV of comments and corrections

Cited by156

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 299 citations.

PMIDTitleJournalYearIn PapersSource
42842067GLP-1R expression and dermatological diseases: a mendelian randomization and real-world study.Endocrine2026https://conductscience.org/library/papers/42842067PubMed
42802751Incretin-based injectable strategies versus intensified insulin for treatment intensification and simplification in type 2 diabetes: a systematic review and meta-analysis.J Diabetes Metab Disord2026https://conductscience.org/library/papers/42802751PubMed
42277362Efficacy and safety of once-weekly basal insulin analogs versus daily basal insulin analogs in adults with type 2 diabetes: a systematic review and meta-analysis.Curr Diab Rep2026https://conductscience.org/library/papers/42277362PubMed
42153087Small-Molecule Oral Versus Injectable Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists: Comparative Efficacy, Safety, and Future Clinical Perspectives.Cureus2026https://conductscience.org/library/papers/42153087PubMed
41465949Gastrointestinal side effects of the non-peptide GLP-1 receptor agonists: A systematic review and meta-analysis.Medicine (Baltimore)2025https://conductscience.org/library/papers/41465949PubMed
39812791Glucagon-like peptide 1 receptor agonists outperform basal insulin in cardiovascular and renal outcomes for type 2 diabetes mellitus: a retrospective cohort study.Acta Diabetol2025https://conductscience.org/library/papers/39812791PubMed
38854306Titration of Basal and Prandial Insulin Doses With the Initiation of Glucagon-Like Peptide-1 Receptor Agonist Therapy.Cureus2024https://conductscience.org/library/papers/38854306PubMed
38792590De-Intensification from Basal-Bolus Insulin Therapy to Liraglutide in Type 2 Diabetes: Predictive Value of Mean Glycaemia during Fasting Test.Life (Basel)2024https://conductscience.org/library/papers/38792590PubMed
38633611Exenatide for obesity in children and adolescents: Systematic review and meta-analysis.Front Pharmacol2024https://conductscience.org/library/papers/38633611PubMed
38433545[Fixed ratio combinations GLP-1RA and basal insulin: literature review].Probl Endokrinol (Mosk)2024https://conductscience.org/library/papers/38433545PubMed
38253801Effects of Organic Zinc on the Growth Performance of Weanling Pigs: A Meta-analysis.Biol Trace Elem Res2024https://conductscience.org/library/papers/38253801PubMed
38249345Glucagon-like peptide-1 receptor agonists as add-on therapy to insulin for type 1 diabetes mellitus.Front Pharmacol2023https://conductscience.org/library/papers/38249345PubMed
37990670Decreased cardiovascular risk factors and inflammation with remission of type 2 diabetes in adults with obesity using a high protein diet: Randomized control trial.Obes Pillars2022https://conductscience.org/library/papers/37990670PubMed
37864379
The efficacy and safety of beinaglutide alone or in combination with insulin glargine in Chinese patients with type 2 diabetes mellitus who are inadequately controlled with oral antihyperglycemic therapy: A multicenter, open-label, randomized trial.
J Diabetes2023https://conductscience.org/library/papers/37864379PubMed
37841938Anti-inflammatory and antioxidant activity of ursolic acid: a systematic review and meta-analysis.Front Pharmacol2023https://conductscience.org/library/papers/37841938PubMed
37362170Treatment strategy for children and adolescents with type 2 diabetes-based on ISPAD Clinical Practice Consensus Guidelines 2022.Clin Pediatr Endocrinol2023https://conductscience.org/library/papers/37362170PubMed
37313232Glucagon-like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes in Youth.touchREV Endocrinol2023https://conductscience.org/library/papers/37313232PubMed
37106129Sex-dependent divergence in the effects of GLP-1 agonist exendin-4 on alcohol reinforcement and reinstatement in C57BL/6J mice.Psychopharmacology (Berl)2023https://conductscience.org/library/papers/37106129PubMed
37035222Fixed-ratio combinations of basal insulin and glucagon-like peptide-1 receptor agonists as a promising strategy for treating diabetes.World J Diabetes2023https://conductscience.org/library/papers/37035222PubMed
36894921The vascular function effects of adding exenatide or meal insulin to basal insulin therapy in early type 2 diabetes.Cardiovasc Diabetol2023https://conductscience.org/library/papers/36894921PubMed

See all 156 cited byDownload CSV of cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
GCG2641PubTator's text mininghttps://conductscience.org/library/genes/2641NCBI Gene
INS3630PubTator's text mininghttps://conductscience.org/library/genes/3630NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • References
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/25220191

GET https://conductscience.org/api/papers/v1/25220191/cited_by?page=2